| References: |
In RPMI 8226, MM.1S, and MM.1R MM cell lines, STF-083010 exhibits cytostatic and cytotoxic activity in a dose and time dependent manner. In MiaPaCa2, Panc0403, and SU8686 cell lines, STF-083010 inhibits XBP1 splicing and blocks IRE1α's endonuclease activity without affecting its kinase activity. In Eμ-TCL1 CLL cells, STF-083010 exhibits about 70% growth inhibition after 3 days culture. In MEC1 and MEC2 cells, STF-083010 produces 20% growth inhibition in 48 h. WaC3 cells respond to treatments with STF-083010 with gradually decreased growth. In human multiple myeloma (MM) xenografts model, STF-083010 (i.p., 30 mg/kg) significantly inhibits the growth of tumor. For the detailed information of STF-083010, the solubility of STF-083010 in water, the solubility of STF-083010 in DMSO, the solubility of STF-083010 in PBS buffer, the animal experiment (test) of STF-083010, the cell expriment (test) of STF-083010, the in vivo, in vitro and clinical trial test of STF-083010, the EC50, IC50,and affinity,of STF-083010, For the detailed information of STF-083010, the solubility of STF-083010 in water, the solubility of STF-083010 in DMSO, the solubility of STF-083010 in PBS buffer, the animal experiment (test) of STF-083010, the cell expriment (test) of STF-083010, the in vivo, in vitro and clinical trial test of STF-083010, the EC50, IC50,and affinity,of STF-083010, Please contact DC Chemicals. |
